HER2 Support Group Forums - View Single Post - Further Development of INCB7839 as a New Oral Treatment for Breast Cancer

tousled1 · 12-16-2007, 12:56 PM

Incyte Corporation (Nasdaq:INCY) announced today that three scientific posters have been presented at the 30th San Antonio Breast Cancer Symposium describing the potential benefits of its selective sheddase inhibitor, INCB7839, in the treatment of metastatic breast cancer.

INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. Currently approved therapies that target the EGFR pathways have shown promising efficacy in metastatic disease, validating these pathways as targets; however, efficacy may be limited due to the fact that these drugs inhibit only one or two of the four HER receptor pathways. In contrast, the sheddase inhibitor, INCB7839, has the potential to inhibit activation through all four of the HER receptors, resulting in more complete inhibition of these pathways

full article: http://www.tradingmarkets.com/.site/...20News/918377/

12-16-2007, 12:56 PM	#1
tousled1 Senior Member Join Date: Feb 2006 Location: Acworth, GA Posts: 2,104	Further Development of INCB7839 as a New Oral Treatment for Breast Cancer Incyte Corporation (Nasdaq:INCY) announced today that three scientific posters have been presented at the 30th San Antonio Breast Cancer Symposium describing the potential benefits of its selective sheddase inhibitor, INCB7839, in the treatment of metastatic breast cancer. INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. Currently approved therapies that target the EGFR pathways have shown promising efficacy in metastatic disease, validating these pathways as targets; however, efficacy may be limited due to the fact that these drugs inhibit only one or two of the four HER receptor pathways. In contrast, the sheddase inhibitor, INCB7839, has the potential to inhibit activation through all four of the HER receptors, resulting in more complete inhibition of these pathways full article: http://www.tradingmarkets.com/.site/...20News/918377/ __________________ Kate Stage IIIC Diagnosed Oct 25, 2005 (age 58) ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2% Neoadjunct chemo: 4 A/C; 4 Taxatore Bilateral mastectomy June 8, 2006 14 of 26 nodes positive Herceptin June 22, 2006 - April 20, 2007 Radiation (X35) July 24-September 11, 2006 BRCA1/BRCA2 negative Stage IV lung mets July 13, 2007 - TCH Single brain met - August 6, 2007 -CyberKnife Oct 2007 - clear brain MRI and lung mets shrinking. March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra